158k views
1 vote
In the EMPA-RED trial, what was assessed as the secondary endpoint

1 Answer

5 votes

Final answer:

In the EMPA-RED trial, the secondary endpoint that was assessed was the effect of Empagliflozin on kidney function in patients with type 2 diabetes and high cardiovascular risk. The assessment of kidney function as a secondary endpoint was important in understanding the overall benefits of the medication.

Step-by-step explanation:

In the EMPA-RED trial, the secondary endpoint that was assessed was the effect of Empagliflozin on kidney function in patients with type 2 diabetes and high cardiovascular risk. The trial evaluated the efficacy and safety of Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, on various outcomes including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke as primary endpoints. The assessment of kidney function as a secondary endpoint was important in understanding the overall benefits of the medication.

secondary endpoint that was assessed was the effect of Empagliflozin on kidney function in patients with type 2 diabetes and high cardiovascular risk. The trial evaluated the efficacy and safety of Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, on various outcomes including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke as primary endpoints. The assessment of kidney function as a secondary endpoint was important in understanding the overall benefits of the medication.

User Pawel
by
8.5k points

Related questions

asked Apr 25, 2024 69.5k views
Jijijijiji asked Apr 25, 2024
by Jijijijiji
7.8k points
1 answer
0 votes
69.5k views
asked Apr 17, 2024 45.5k views
Pierre Vieira asked Apr 17, 2024
by Pierre Vieira
7.9k points
1 answer
5 votes
45.5k views
1 answer
4 votes
76.8k views